{"id":"W2895829368","doi":"10.1093/annonc/mdy299.014","title":"A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults: Epithelioid sarcoma cohort (NCT02601950)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Medicine; Tolerability; Epithelioid sarcoma; Internal medicine; Clinical endpoint; Oncology; Interim analysis; Response Evaluation Criteria in Solid Tumors; Sarcoma; Phases of clinical research; Cohort; Adverse effect; Clinical trial; Surgery; Pathology; Immunohistochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001823429,0.001119681,0.001099535,0.0002612957,0.00042341,0.0006268636,0.0006206686,0.0008475443,0.005349134],"category_scores_gemma":[0.0008489928,0.0004473078,0.0008638807,0.000352944,0.0005113717,0.0005803959,0.0004294198,0.001800507,0.001191219],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006680679,"about_ca_system_score_gemma":0.00162607,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001153234,"about_ca_topic_score_gemma":0.004038461,"domain_scores_codex":[0.9996902,0.0001365672,0.00002001696,0.00006784533,0.00003763108,0.00004770844],"domain_scores_gemma":[0.9994087,0.00005558367,0.0001213624,0.00005771371,0.00006629214,0.0002903253],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7236261,0.04312257,0.04675717,0.001231092,0.003875367,0.0008636218,0.0004839732,0.002590024,0.06605014,0.0006088073,0.02129344,0.08949773],"study_design_scores_gemma":[0.6485609,0.2503881,0.07160088,0.00009333692,0.001876403,0.001586855,0.0001982018,0.001678474,0.005818259,0.0005177101,0.01762785,0.00005301896],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9797671,0.001352366,0.0008997215,0.0006434626,0.00009978322,0.006091772,0.008331582,0.0001333439,0.002680964],"genre_scores_gemma":[0.9579276,0.001820798,0.00532941,0.001801942,0.0001702159,0.00804906,0.01988597,0.00006302951,0.004952025],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005349134,"threshold_uncertainty_score":0.01789463,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02915143392198739,"score_gpt":0.3619184141284154,"score_spread":0.332766980206428,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}